全文获取类型
收费全文 | 15089篇 |
免费 | 1036篇 |
国内免费 | 245篇 |
专业分类
耳鼻咽喉 | 459篇 |
儿科学 | 203篇 |
妇产科学 | 252篇 |
基础医学 | 2435篇 |
口腔科学 | 246篇 |
临床医学 | 1071篇 |
内科学 | 3254篇 |
皮肤病学 | 397篇 |
神经病学 | 1004篇 |
特种医学 | 1259篇 |
外科学 | 2051篇 |
综合类 | 36篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 366篇 |
眼科学 | 507篇 |
药学 | 1252篇 |
中国医学 | 226篇 |
肿瘤学 | 1349篇 |
出版年
2023年 | 76篇 |
2022年 | 82篇 |
2021年 | 561篇 |
2020年 | 320篇 |
2019年 | 475篇 |
2018年 | 538篇 |
2017年 | 420篇 |
2016年 | 660篇 |
2015年 | 892篇 |
2014年 | 1021篇 |
2013年 | 1163篇 |
2012年 | 1642篇 |
2011年 | 1475篇 |
2010年 | 988篇 |
2009年 | 822篇 |
2008年 | 1070篇 |
2007年 | 938篇 |
2006年 | 794篇 |
2005年 | 658篇 |
2004年 | 536篇 |
2003年 | 448篇 |
2002年 | 396篇 |
2001年 | 58篇 |
2000年 | 44篇 |
1999年 | 38篇 |
1998年 | 36篇 |
1997年 | 26篇 |
1996年 | 26篇 |
1995年 | 14篇 |
1994年 | 20篇 |
1993年 | 23篇 |
1992年 | 11篇 |
1991年 | 14篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 9篇 |
1987年 | 13篇 |
1986年 | 4篇 |
1985年 | 7篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1973年 | 1篇 |
1968年 | 1篇 |
1962年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Hyun Cheol Chung MD PhD Yoon-Koo Kang MD PhD Zhendong Chen MD Yuxian Bai MD Wan Zamaniah Wan Ishak MD Byoung Yong Shim MD Young Lee Park MD Dong-Hoe Koo MD PhD Jianwei Lu MD Jianming Xu MD Hong Jae Chon MD Li-Yuan Bai MD Shan Zeng MD Ying Yuan MD Yen-Yang Chen MD Kangsheng Gu MD Wen Yan Zhong PhD Shu Kuang MD Chie-Schin Shih MD Shu-Kui Qin MD PhD 《Cancer》2022,128(5):995-1003
2.
Sleep and Breathing - The presence of periodic limb movements during sleep (PLMS) varies among patients with obstructive sleep apnea (OSA) undergoing treatment with continuous positive airway... 相似文献
3.
Kim Jung Wan Eom Youngsub Park Wonkyung Song Jong Suk Jeong Ji Won Park Seh Kwang Kim Hyo Myung 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(10):3275-3283
Graefe's Archive for Clinical and Experimental Ophthalmology - To compare visual outcomes between two types of mix-and-match implanted trifocal extended-depth-of-focus (EDoF) and trifocal... 相似文献
4.
5.
6.
Min Hee Hong MD Seong Gu Heo PhD Yun-Gyoo Lee MD PhD Hyo Song Kim MD PhD Keon Uk Park MD PhD Hoon-Gu Kim MD PhD Yoon Ho Ko MD PhD Ik-Joo Chung MD PhD Young Joo Min MD PhD Min Kyoung Kim MD PhD Kyu Ryung Kim PhD Jinseon Yoo MS Tae-Min Kim MD PhD Hye Ryun Kim MD PhD Byoung Chul Cho MD PhD 《Cancer》2020,126(20):4521-4531
7.
Young Hyo Choi Min Yong Kang Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Chan Kyo Kim Byung Kwan Park Hyun Moo Lee 《Clinical genitourinary cancer》2019,17(1):e19-e25
Background
The purpose of the study was to compare cancer detection rates between 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and multiparametric magnetic resonance imaging (mpMRI)-guided target prostate biopsy (MRI-TBx) according to prostate-specific antigen (PSA) level in biopsy-naive patients.Patients and Methods
A retrospective study was conducted in 2009 biopsy-naive patients with suspected prostate cancer (PSA ≤20 ng/mL). Patients underwent TRUS-Bx (n = 1786) or MRI-guided target prostate biopsy (MRI-TBx; n = 223) from September 2013 to March 2017 and were stratified according to each of 4 PSA cutoffs. MRI-TBx was performed on lesions with Prostate Imaging Reporting and Data System (PI-RADS) scores of 3 to 5 on mpMRI. Clinically significant prostate cancer (csPCa) was defined as Gleason ≥7. Propensity score matching was performed using the prebiopsy variables, which included age, PSA, prostate volume, and PSA density.Results
Propensity score matching resulted in 222 patients in each group. There were significant differences between the TRUS-Bx and MRI-TBx groups in the overall detection rates of prostate cancer (41.4% vs. 55.4%; P = .003) and csPCa (30.1% vs. 42.8%; P = .005). However, across PSA cutoffs, MRI-TBx detected more prostate cancer than TRUS-Bx at PSA levels of 2.5 to <4 (29.5% vs. 56.6%; P < .001). The csPCa detection rates of TRUS-Bx and MRI-TBx did not differ significantly within the PSA cutoffs. There was a significantly higher detection rate of prostate cancer and csPCa in lesions with PI-RADS scores 4 and 5 than in those with a score of 3.Conclusion
Prebiopsy mpMRI and subsequent targeted biopsy had a higher detection rate than TRUS-Bx in patients with prostate cancer and csPCa. 相似文献8.
Joanne E. Mortimer Laura Kruper Jae Jung Louise Wong Jill Cooper Daphne Stewart Samuel Chung Kim Wai Yu Sanjeet Dadwal Yuan Yuan 《Cancer chemotherapy and pharmacology》2020,85(3):501-507
We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem.
Treating physicians and advanced practice partners identified women who developed infections while on treatment with pertuzumab and trastuzumab alone or in combination with chemotherapy and enrolled them onto this registry trial. Between March, 2014 and May, 2017, 48 patients with HER2-positive breast cancers were reported to have 59 individual infections. The median age was 48 years. Twenty-four patients received neoadjuvant therapy, 17 were treated for metastatic disease, and 7 were treated in the adjuvant setting. Pertuzumab and trastuzumab were combined with carboplatin and docetaxel in 24 (49%) patients, docetaxel in 10 (21%), nab-paclitaxel in 12 (24%), and without other agents in 2 (4%). Granulocyte growth factors were administered in 24 (49%) patients and no patients were documented to be neutropenic. Folliculitis developed in 25 (52%) patients and was counted as a single infection. Abscesses developed at a number of sites in 24 (49%) patients, including a septic knee requiring total knee replacement. Paronychia occurred in 7 (15%) patients, and 5 (10%) developed cellulitis. When cultures were obtained, Gram-positive cocci were consistently identified. Hypogammaglobulinemia was documented in 14 (36%) of the 33 patients tested. Our data continue to support an increased risk of infections with Gram-positive cocci as a potentially serious adverse event in women treated with pertuzumab and trastuzumab. 相似文献
9.
10.